Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Stimulating the development of drug treatments to improve cognition in schizophrenia.

Green MF.

Annu Rev Clin Psychol. 2007;3:159-80. Review.

PMID:
17716052
2.

Drug initiatives to improve cognitive function.

Marder SR.

J Clin Psychiatry. 2006;67 Suppl 9:31-5; discussion 36-42.

PMID:
16965187
3.

The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.

Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, Essock S, Fenton WS, Frese FJ 3rd, Gold JM, Goldberg T, Heaton RK, Keefe RS, Kraemer H, Mesholam-Gately R, Seidman LJ, Stover E, Weinberger DR, Young AS, Zalcman S, Marder SR.

Am J Psychiatry. 2008 Feb;165(2):203-13. doi: 10.1176/appi.ajp.2007.07010042. Epub 2008 Jan 2.

PMID:
18172019
4.

Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study.

Green MF, Nuechterlein KH, Kern RS, Baade LE, Fenton WS, Gold JM, Keefe RS, Mesholam-Gately R, Seidman LJ, Stover E, Marder SR.

Am J Psychiatry. 2008 Feb;165(2):221-8. doi: 10.1176/appi.ajp.2007.07010089. Epub 2008 Jan 2.

PMID:
18172017
5.

The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?

Buchanan RW, Keefe RS, Umbricht D, Green MF, Laughren T, Marder SR.

Schizophr Bull. 2011 Nov;37(6):1209-17. doi: 10.1093/schbul/sbq038. Epub 2010 Apr 21.

6.
8.

The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization.

Kern RS, Nuechterlein KH, Green MF, Baade LE, Fenton WS, Gold JM, Keefe RS, Mesholam-Gately R, Mintz J, Seidman LJ, Stover E, Marder SR.

Am J Psychiatry. 2008 Feb;165(2):214-20. doi: 10.1176/appi.ajp.2007.07010043. Epub 2008 Jan 2.

PMID:
18172018
9.

New paradigms for treatment development.

Stover EL, Brady L, Marder SR.

Schizophr Bull. 2007 Sep;33(5):1093-9. Epub 2007 Aug 2.

10.

Identifying cognitive mechanisms targeted for treatment development in schizophrenia: an overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative.

Carter CS, Barch DM, Buchanan RW, Bullmore E, Krystal JH, Cohen J, Geyer M, Green M, Nuechterlein KH, Robbins T, Silverstein S, Smith EE, Strauss M, Wykes T, Heinssen R.

Biol Psychiatry. 2008 Jul 1;64(1):4-10. doi: 10.1016/j.biopsych.2008.03.020. Epub 2008 May 7.

11.

Targeting cognitive deficits in schizophrenia: a review of the development of a new class of medicines from the perspective of community mental health researchers.

Tcheremissine OV, Castro MA, Gardner DR.

Expert Opin Investig Drugs. 2012 Jan;21(1):7-14. doi: 10.1517/13543784.2012.634798. Epub 2011 Nov 8. Review.

PMID:
22059602
12.

[Cognitive deficit in schizophrenia: MATRICS Consensus Cognitive Battery].

Rodríguez-Jiménez R, Bagney A, Moreno-Ortega M, García-Navarro C, Aparicio AI, López-Antón R, de la Oliva J, Jiménez-Arriero MÁ, Santos JL, Lobo A, Palomo T.

Rev Neurol. 2012 Nov 1;55(9):549-55. Review. Spanish.

13.

Wayne Fenton's impact on academic neuroscience.

Geyer MA, Tamminga CA.

Schizophr Bull. 2007 Sep;33(5):1156-9. Epub 2007 Jul 7.

14.

Cognitive neuroscience and schizophrenia: translational research in need of a translator.

Cohen JD, Insel TR.

Biol Psychiatry. 2008 Jul 1;64(1):2-3. doi: 10.1016/j.biopsych.2008.04.031. No abstract available.

PMID:
18549873
15.

[Approaches to the development of the Japanese academic version of the MATRICS Consensus Cognitive Battery].

Sato T, Sora I.

Nihon Shinkei Seishin Yakurigaku Zasshi. 2011 Nov;31(5-6):241-4. Japanese.

PMID:
22256613
16.

Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far?

Keefe RS, Buchanan RW, Marder SR, Schooler NR, Dugar A, Zivkov M, Stewart M.

Schizophr Bull. 2013 Mar;39(2):417-35. doi: 10.1093/schbul/sbr153. Epub 2011 Nov 22. Review.

17.

Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria.

Green MF, Nuechterlein KH, Gold JM, Barch DM, Cohen J, Essock S, Fenton WS, Frese F, Goldberg TE, Heaton RK, Keefe RS, Kern RS, Kraemer H, Stover E, Weinberger DR, Zalcman S, Marder SR.

Biol Psychiatry. 2004 Sep 1;56(5):301-7. Review.

PMID:
15336511
18.

Medicine. What are the right targets for psychopharmacology?

Hyman SE, Fenton WS.

Science. 2003 Jan 17;299(5605):350-1. No abstract available.

PMID:
12532001
19.

Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review.

Saavedra-Velez C, Yusim A, Anbarasan D, Lindenmayer JP.

J Clin Psychiatry. 2009 Jan;70(1):104-12. Epub 2008 Nov 18. Review.

PMID:
19026265
20.

Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia.

Young JW, Powell SB, Risbrough V, Marston HM, Geyer MA.

Pharmacol Ther. 2009 May;122(2):150-202. doi: 10.1016/j.pharmthera.2009.02.004. Epub 2009 Mar 6. Review.

Items per page

Supplemental Content

Write to the Help Desk